Oncotype DX assay linked to decrease in chemotherapy use in younger patients

[News]

In what's believed to be one of the largest population-based studies of Oncotype DX ever conducted, researchers at The University of Texas MD Anderson Cancer Center have found that the commercial diagnostic tool, Oncotype DX, was associated with a decrease in chemotherapy use in younger patients, but not in those over 66 years of age.

More... (http://www.news-medical.net/news/20141214/Oncotype-DX-assay-linked-to-decrease-in-chemotherapy-use-in-younger-patients.aspx)